Low Threshold Buprenorphine: What do we know and where do we go from here?

Andrea Jakubowski, MD, MS
Montefoire

ABSTRACT:
Over two decades into the opioid overdose crisis, buprenorphine remains underutilized and inaccessible to many people with opioid use disorder. Improving accessibility and utilization requires attention to where treatment is offered and how patients are treated once they enter care. In this presentation, Dr. Jakubowski will describe: 1) principles of low-threshold buprenorphine; 2) clinical and implementation data on syringes services program (SSP)-based buprenorphine programs; 3) early findings from Dr. Jakubowski’s NIDA K23 examining implementation of long-acting injectable buprenorphine in SSP and primary care clinics; 4) description and rationale of CTN-0155: Low-Threshold Buprenorphine Treatment at Syringe Services Programs: A Type I Hybrid Effectiveness-implementation Trial.